양극성 장애용 기분안정제 시장 : 약제 유형별, 적응증별, 투여 경로별, 환자층별, 유통 채널별, 지역별

Bipolar Disorder Mood Stabilizers Market is estimated to be valued at USD 2.30 Bn in 2026 and is expected to reach USD 2.75 Bn by 2033, growing at a compound annual growth rate (CAGR) of 2.7% from 2026 to 2033.

Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Mood stabilizers are a class of drugs used to prevent or treat the extreme mood swings associated with bipolar disorder. The global bipolar disorder mood stabilizers market has been gaining significant traction over the past few years, owing to the rising prevalence of bipolar disorder worldwide and growing awareness regarding its effective treatment options. Increasing R&D investments by pharmaceutical companies to develop novel treatment alternatives are also propelling the market growth.

Market Dynamics

The global bipolar disorder mood stabilizers market is primarily driven by the growing prevalence of bipolar disorder caused by genetic and environmental factors such as traumatic life events and substance abuse. As per WHO statistics released in July 2025, over 45 million people worldwide suffer from bipolar disorder. Furthermore, rising awareness about available treatment options and increased healthcare spending are encouraging more patients to seek medical help. Meanwhile, continuous innovations and introduction of new drug formulations with higher efficacy and improved tolerability are helping expand the market reach. However, the market potential is still untapped in underdeveloped economies due to low diagnosis and treatment rates of mental disorders. High costs of branded drugs also limit their adoption in price-sensitive markets. Nonetheless, ongoing clinical trials for advanced drugs, especially for treatment-resistant patients, are expected to introduce new opportunities during the forecast period.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global bipolar disorder mood stabilizers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eli Lilly and Company, AstraZeneca PLC, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, GlaxoSmithKline, Sanofi S.A., Merck & Co., Teva Pharmaceutical Industries, Novartis AG, Otsuka Pharmaceutical, H. Lundbeck A/S, Takeda Pharmaceutical Company, and Alkermes plc
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global bipolar disorder mood stabilizers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder mood stabilizers market

Market Segmentation

• Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
• Lithium
  • Lithium Carbonate
  • Lithium Citrate
• Anticonvulsants
  • Valproic Acid/Valproate/Divalproex Sodium
  • Lamotrigine
  • Carbamazepine
  • Oxcarbazepine
  • Topiramate
• Atypical Antipsychotics
  • Aripiprazole
  • Olanzapine
  • Quetiapine
  • Risperidone
  • Lurasidone
  • Ziprasidone
  • Asenapine
• Calcium Channel Blockers
• Others (Combination Therapies, etc.)
• Indication Insights (Revenue, USD Bn, 2021 - 2033)
• Bipolar I Disorder
• Bipolar II Disorder
• Cyclothymic Disorder
• Mixed Features Bipolar Disorder
• Rapid Cycling Bipolar Disorder
• Others
• Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
• Oral
• Parenteral/Injectable
• Transdermal
• Others
• Patient Demographics Insights (Revenue, USD Bn, 2021 - 2033)
• Age Groups
• Children and adolescents
• Adults
• Elderly
• Gender
• Male
• Female
• Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Eli Lilly and Company
• AstraZeneca PLC
• Johnson & Johnson
• Pfizer Inc.
• AbbVie Inc.
• Bristol-Myers Squibb
• GlaxoSmithKline
• Sanofi S.A.
• Merck & Co.
• Teva Pharmaceutical Industries
• Novartis AG
• Otsuka Pharmaceutical
• Lundbeck A/S
• Takeda Pharmaceutical Company
• Alkermes plc

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Bipolar Disorder Mood Stabilizers Market, By Drug Type
  • Global Bipolar Disorder Mood Stabilizers Market, By Indication
  • Global Bipolar Disorder Mood Stabilizers Market, By Route of Administration
  • Global Bipolar Disorder Mood Stabilizers Market, By Patient Demographics
  • Global Bipolar Disorder Mood Stabilizers Market, By Distribution Channel
  • Global Bipolar Disorder Mood Stabilizers Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Bipolar Disorder Mood Stabilizers Market, By Drug Type, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Lithium
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Lithium Carbonate
    • Lithium Citrate
• Anticonvulsants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Valproic Acid/Valproate/Divalproex Sodium
    • Lamotrigine
    • Carbamazepine
    • Oxcarbazepine
    • Topiramate
• Atypical Antipsychotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Aripiprazole
    • Olanzapine
    • Quetiapine
    • Risperidone
    • Lurasidone
    • Ziprasidone
    • Asenapine
• Calcium Channel Blockers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others (Combination Therapies, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Bipolar Disorder Mood Stabilizers Market, By Indication, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Bipolar I Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Bipolar II Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Cyclothymic Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Mixed Features Bipolar Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Rapid Cycling Bipolar Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Bipolar Disorder Mood Stabilizers Market, By Route of Administration, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Parenteral/Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Transdermal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Bipolar Disorder Mood Stabilizers Market, By Patient Demographics, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Age Groups
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Children and adolescents
    • Adults
    • Elderly
• Gender
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Male
    • Female

8. Global Bipolar Disorder Mood Stabilizers Market, By Distribution Channel, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Bipolar Disorder Mood Stabilizers Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Otsuka Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lundbeck A/S
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Alkermes plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us